TA-25 rises ahead of expected rate cut

Israeli stocks were higher in light trading Sunday as investors awaited the pending interest-rate decision by the Bank of Israel, expecting a second consecutive quarter-point cut from the current 5.25 percent benchmark rate.

By ROBERT DANIEL, MARKETWATCH
November 27, 2006 08:38
2 minute read.

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

MarketWatch: In-depth global business coverage Israeli stocks were higher in light trading Sunday as investors awaited the pending interest-rate decision by the Bank of Israel, expecting a second consecutive quarter-point cut from the current 5.25 percent benchmark rate. "Positive macroeconomic numbers and expectations for a [quarter-point] rate cut [Monday] and further cuts in the months ahead" are driving the market, said Richard Gussow, senior analyst at Excellence Nessuah in Ramat Gan. The Tel Aviv Stock Exchange's benchmark TA-25 index closed 0.46% higher at 919.49, the TA-100 was up 0.29% at 927.09, and the Tel-Tech 15 index of top technology stocks is 0.2% ahead at 383.46. The TA-25 and TA-100 are again near their records, 924.81 and 935.51, respectively, which were set on Thursday. The Tel-Tech topped out at 482.78 on January 20, 2004. The most-active issue is Bank Leumi, finishing down 0.1% at NIS 17.04 while accounting for some 4.6% of the total TASE volume of $242 million. That, in turn, is less than three-quarters of the exchange's average daily trading through October of $332m. Active within the TA-25 were Teva Pharmaceutical up 0.9% at NIS 141.7, telecom provider Bezeq up 0.8% at NIS 6.65 and Israel Chemicals up 1.3% at 24.35. TA-25 losers included two real estate firms, Africa Israel Investments, down 2.7% at NIS 292 and Gazit Globe, off 1.6% at NIS 56.1. The Tel Aviv Real Estate index fell 1.4% to 669.74. The residential and industrial builder Dori jumped 12%. The company said in a statement that General Electric would pay Dori €25m. for 20.9% of a subsidiary that focuses on residential building in Poland. Dori expects a capital gain of NIS 35m. on the deal. The Tel Aviv Finance Index added 0.72% to 1,172.49. Helping it along were four of the banks: Discount, up 0.9% to NIS 8.32, First International Issue 5, up 1.6% to NIS 53.35, Bank Hapoalim, up less than 0.1% to NIS 20.91 and Mizrahi-Tefahot, up 1.2% to NIS 31.15. On the losing side, besides Leumi, which is scheduled to report earnings later this week, was Union Bank, down 0.9% at NIS 20.88. Five major insurers also flashed green: Clal, up 2.3% at NIS 102.4, Direct, up 1.3% at NIS 18.55, Harel up 0.7% at NIS 216.8, Menorah Mivtach, up 0.5% at NIS 50.8, and Migdal up 1% at NIS 5.92. Active within the Tel-Tech were defense contractor Elbit Systems, up 0.9% at NIS 143.7, and Verifone, up 1.5% at NIS 148.2. MarketWatch: In-depth global business coverage

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS